Last reviewed · How we verify
NCT06994208: MELA_2025
Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.
trial in Melanoma of Skin in 25 participants. Currently enrolling.
1 September 2027
Quick facts
| Lead sponsor | Ente Ospedaliero Ospedali Galliera |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 2 December 2025 |
| Primary completion | 1 September 2027 |
| Estimated completion | 31 August 2028 |
| Sites | 1 location across Italy |
Conditions studied
- Melanoma of Skin — all drugs for Melanoma of Skin →
Sponsor
Ente Ospedaliero Ospedali Galliera — full company profile →
Who can join
Adults 18 to 39, any sex, with Melanoma of Skin. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of the study is to analyse a local cohort of patients aged 18-39 years with melanoma diagnosis in order to determine the prevalence of the disease in this age group. Secondary objectives are the following: * To identify risk factors associated with melanoma in young people. * To characterise the phenotype and dermoscopic features of melanoma in patients aged 18-39 years. * To analyse the relationship between the clinical and histopathological features of melanoma in young people. * To identify the mutational status of B-RAF in the sample of patients analysed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06994208
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Melanoma of Skin
Currently open trials in the same condition.
- NCT06965231 — Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial · Phase 2 · recruiting
- NCT06784648 — Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metast · Phase 1, PHASE2 · active not recruiting
- NCT07031830 — APA (Adapted Physical Activity) for Patients With Advanced Melanoma · recruiting
Other Ente Ospedaliero Ospedali Galliera trials
Trials by the same sponsor.
- NCT07486336 — Awareness Neuraxial Versus General Anesthesia in Frail Patients Undergoing Laparoscopic or Robotic Abdominopelvic Surger · NA · not yet recruiting
- NCT07483840 — Analgesic Techniques for Robotic Prostatectomy Procedures · NA · not yet recruiting
- NCT05601700 — Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer (LEPRE Trial) · Phase 3 · recruiting
- NCT07187986 — Sound Acupuncture in Painful Chemotherapy-Related Neuropathies · NA · completed
- NCT04932863 — BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06994208 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ente Ospedaliero Ospedali Galliera
- Last refreshed: 19 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06994208.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing